https://faqsir.com/company/oryzon-genomics-sa/feed <![CDATA[Oryzon Genomics S.A. — Announcements]]> Oryzon Genomics S.A. (BME:ORY, OTC PINK:ORYZF) announcements published on FAQSIR. AI-generated content. Paid-for issuer communication. Not investment advice. Published in partnership with Oryzon Genomics S.A.. Oryzon Genomics S.A. pays FAQSIR a subscription fee for this page. 2026-10-14T13:24:00+00:00 <![CDATA[Oryzon receives EMA authorisation to initiate HOPE-2 Phase IIa study in PMS]]> https://faqsir.com/3359 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:31+00:00 2026-10-14T13:21:31+00:00 <![CDATA[Oryzon reports U.S. Notice of Allowance for iadademstat-gilteritinib patent application]]> https://faqsir.com/3355 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:15+00:00 2026-10-14T13:21:15+00:00 <![CDATA[Oryzon reports first-half 2026 results alongside clinical and financing updates]]> https://faqsir.com/3365 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:48+00:00 2026-10-14T13:21:48+00:00 <![CDATA[Oryzon reports U.S. patent grant covering vafidemstat in non-aggressive BPD symptoms]]> https://faqsir.com/3367 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:49+00:00 2026-10-14T13:21:49+00:00 <![CDATA[Oryzon completes €12 million capital increase and signs conditional COFIDES subscription agreement]]> https://faqsir.com/3360 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:34+00:00 2026-10-14T13:21:34+00:00 <![CDATA[Oryzon Reports Updated Iadademstat Data from AML Trials at EHA 2026]]> https://faqsir.com/3368 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:53+00:00 2026-10-14T13:21:53+00:00 <![CDATA[Oryzon reports first patient enrolled in Phase II IDEAL trial for essential thrombocythemia]]> https://faqsir.com/3356 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:29+00:00 2026-10-14T13:21:29+00:00 <![CDATA[Oryzon reports first-quarter 2026 results as clinical programmes advance]]> https://faqsir.com/3377 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:22:37+00:00 2026-10-14T13:22:37+00:00 <![CDATA[Oryzon to Present Updated Iadademstat Data in Two AML Trials at EHA 2026]]> https://faqsir.com/3364 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:48+00:00 2026-10-14T13:21:48+00:00 <![CDATA[Oryzon reports U.S. Notice of Allowance for vafidemstat patent application]]> https://faqsir.com/3362 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:37+00:00 2026-10-14T13:21:37+00:00 <![CDATA[Oryzon reports U.S. patent grant for iadademstat and venetoclax combinations]]> https://faqsir.com/3363 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:42+00:00 2026-10-14T13:21:42+00:00 <![CDATA[Oryzon reports Mexican decision to grant patent for iadademstat combinations]]> https://faqsir.com/3357 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:30+00:00 2026-10-14T13:21:30+00:00 <![CDATA[Oryzon reports 2025 results as clinical programmes advance]]> https://faqsir.com/3374 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:22:18+00:00 2026-10-14T13:22:18+00:00 <![CDATA[Oryzon receives EMA authorisation to begin Phase II iadademstat study in essential thrombocythemia]]> https://faqsir.com/3370 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:57+00:00 2026-10-14T13:21:57+00:00 <![CDATA[Oryzon appoints Rolando Gutierrez-Esteinou as Chief Medical Officer for CNS programmes]]> https://faqsir.com/3358 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:31+00:00 2026-10-14T13:21:31+00:00 <![CDATA[Oryzon reports first dosing in Yale-led Phase Ib iadademstat study for ES-SCLC]]> https://faqsir.com/3366 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:49+00:00 2026-10-14T13:21:49+00:00 <![CDATA[Oryzon receives Japanese patent grant decision for vafidemstat application]]> https://faqsir.com/3372 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:22:00+00:00 2026-10-14T13:22:00+00:00 <![CDATA[Oryzon receives Japanese decision to grant iadademstat combination patent]]> https://faqsir.com/3361 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:37+00:00 2026-10-14T13:21:37+00:00 <![CDATA[Oryzon shareholders approve resolutions at December 2025 extraordinary meeting]]> https://faqsir.com/3369 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:53+00:00 2026-10-14T13:21:53+00:00 <![CDATA[Oryzon reports updated iadademstat combination data in AML at ASH]]> https://faqsir.com/3371 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:21:59+00:00 2026-10-14T13:21:59+00:00 <![CDATA[Oryzon reports $4.6 million net loss for nine months ended September 30, 2025]]> https://faqsir.com/3378 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:22:38+00:00 2026-10-14T13:22:38+00:00 <![CDATA[Oryzon says three iadademstat abstracts accepted for ASH 2025]]> https://faqsir.com/3379 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:22:47+00:00 2026-10-14T13:22:47+00:00 <![CDATA[Oryzon enrols first patient in Phase Ib RESTORE trial of iadademstat for sickle cell disease]]> https://faqsir.com/3376 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:22:27+00:00 2026-10-14T13:22:27+00:00 <![CDATA[Oryzon appoints Dr. Iman Barilero as Senior Advisor for Regulatory Affairs]]> https://faqsir.com/3373 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:22:04+00:00 2026-10-14T13:22:04+00:00 <![CDATA[Oryzon receives FDA feedback on Phase III vafidemstat protocol for BPD]]> https://faqsir.com/3380 AI-generated content. Paid-for issuer communication. Not investment advice. 2026-10-14T13:24:00+00:00 2026-10-14T13:24:00+00:00